Novel Biodegradable Fluorescent Nanoparticles for Early Detection of Pancreatic Cancer

Summary of the technology

' Provides early detection of pancreatic cancer, significantly increasing the potential for successful treatment outcomes
' Utilizes targeted nanoparticles, enhancing specificity and reducing false positives in diagnostic imaging
' Supports the development of personalized medicine approaches by enabling precise lesion targeting

Georgetown University

OVERVIEW

Georgetown University presents an innovative approach for the early detection of pancreatic cancer and precancerous lesions through biodegradable fluorescent polyplex nanoparticles (NPs). These NPs specifically target the Cholecystokinin-B Receptor (CCK-BR), offering a groundbreaking method for diagnosing pancreatic lesions in vivo. The targeted NPs can be conjugated with fluorophores or radioactive molecules, enabling the early detection of pancreatic intraepithelial neoplasia (PanIN) lesions, which are not visible through current imaging techniques.

BACKGROUND

Pancreatic cancer's late diagnosis results in low survival rates, highlighting a significant unmet need in the oncology market for early detection methods. This technology, with its potential for screening high-risk individuals and monitoring treatment responses, opens up considerable market opportunities in the diagnostic and therapeutic sectors of healthcare.

Benefit

Increased Accuracy:Enhances the detection of early-stage pancreatic lesions, improving diagnostic precision.

● Non-invasive:Offers a safer, patient-friendly alternative to traditional diagnostic methods.

Cost-Effective:Potentially reduces healthcare costs through early intervention and improved treatment planning.

Versatile application, including diagnostic imaging and therapeutic agent delivery.

Market Application

Diagnostic Imaging:For early detection and monitoring of pancreatic cancer.

Personalized Medicine:As a tool in tailoring patient-specific therapeutic strategies.

Pharmaceutical Research:In the development of targeted drug delivery systems.

Publications

US Published Patent Appln n.17/925,582

  • Smith JP, Whitcomb DC, Matters GL, Brand RE, Liao J, Huang YJ, and Frazier ML. Distribution of the CCK-B receptor genotype between pancreatic cancer patients and controls and its impact on survival. Pancreas, 44: 236-242. PMID: 25469546.
  • Smith JP, Chen W, Shivapurkar N, Gerber M, Tucker RD, Kallakury B, Dasa SSK, Kularatne RN, Stern ST. Target-Specific Nanoparticle Polyplex Down-Regulates MutantKrasto Prevent Pancreatic Carcinogenesis and Halt Tumor Progression. Int J Mol Sci. 2023 Jan 1;24(1):752. doi: 10.3390/ijms24010752. PMID: 36614194; PMCID: PMC9821664.

Related Keywords

  • Pharmaceutics
  • Biological Sciences
  • Medicine, Human Health
  • Pharmaceutical Products / Drugs
  • Cytology, Cancerology, Oncology
  • Diagnostics, Diagnosis
  • Diagnostic
  • Clinical Medicine
  • Oncology

About Georgetown University

Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.

Georgetown University

Never miss an update from Georgetown University

Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide

Georgetown University

Send a request for information
to Georgetown University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support